Hong Kong IPO disclosure precedents · 99 companies, 99 items
Goodwill arising from acquisitions allocated to cash-generating units, with annual impairment testing based on value-in-use or DCF models and disclosure of key assumptions such as revenue growth, margins, discount rates and sensitivity analysis, generally with no impairment recognized.
As of December 31, 2023, 2024 and 2025, our goodwill amounted to RMB24.1 million, RMB24.5 million and RMB24.0 million, respectively.
Financial Information · p. 243
The key assumptions on which we have based our cash flow projections to undertake impairment testing of goodwill are (i) budgeted revenue — amounts of the budgeted sales are based on the historical data and our expectation of the future market; (ii) budgeted gross margins — the basis used to determine the value assigned to the budgeted gross margins is the average gross margins achieved in the year immediately before the budget year; and (iii) discount rate — the discount rate used is before tax and reflects specific risks relating to the relevant unit.
Financial Information · p. 243
Considering there was still sufficient headroom based on the assessment, we believe that a reasonably possible change in the above key parameters would not cause the carrying amount of the Zentel Japan cash-generating unit to exceed its recoverable amount as of December 31, 2023, 2024 and 2025.
Goodwill has been allocated to the cash-generating unit (‘‘CGU’’), namely eLum, and is tested for impairment annually.
Financial Information · p. 209
As of December 31, 2024 and 2025, the recoverable amount of the CGU exceeded its carrying amount by approximately RMB28.5 million and RMB34.1 million, respectively.
Financial Information · p. 210
Based on the above assessments and sensitivity analyses, the recoverable amounts remained in excess of the carrying amounts, and therefore no impairment was considered necessary.
Our goodwill is recognized from our acquisition of Puxiang TCM Hospital. We recorded goodwill of RMB60.2 million, RMB60.2 million and RMB60.2 million as of December 31, 2023, 2024 and 2025, respectively.
Financial Information · p. 242
These calculations use cash flow projections based on financial budgets approved by management covering a five-year period.
We recorded goodwill of HKD1,292.9 million as of each of December 31, 2023, 2024 and 2025.
Financial Information · p. 177
The recoverable amount of the travel-document and related services CGU has been determined based on a value in use calculation using cash flow projections based on financial budgets covering through 2047 approved by our senior management.
Financial Information · p. 177
The discount rates applied to cash flow projections are 11.0%, 11.0% and 10.0% respectively during the Track Record Period.
Our goodwill increased from nil as of December 31, 2024 to RMB73.8 million as of December 31, 2025 due to our acquisition of Shanghai Celludye in August 2025.
Financial Information · p. 215
This calculation was based on cash flow projections from management-approved financial budgets over a five-year period, with a pre-tax discount rate of 13.9% and a terminal growth rate of 2%.
Financial Information · p. 215
As of December 31, 2025, the recoverable amount of the CGU of Shanghai Celludye exceeded its carrying amount by approximately RMB48.9 million, providing sufficient headroom.
Our goodwill increased by RMB2.0 million from RMB24.1 million as of December 31, 2023 to RMB26.2 million as of December 31, 2024, resulting from the acquisition of 70.0% equity interest of NGTEC from two Independent Third Parties at a consideration of EUR663,137.00 in July 2024.
Financial Information · p. 242
We determine whether goodwill is impaired at least on an annual basis. Based on the results of the impairment testing, our management determined that goodwill was not impaired as of December 31, 2023, 2024 and 2025.
Our goodwill increased significantly from RMB5,061.7 million as of December 31, 2023 to RMB11,093.2 million as of December 31, 2024, primarily due to our acquisition of APT Medical Inc. in 2024.
Financial Information · p. 250
We did not recognize any impairment loss of goodwill during the Track Record Period.
Financial Information · p. 250
Our other intangible assets increased significantly from RMB1,958.9 million as of December 31, 2023 to RMB6,091.2 million as of December 31, 2024, primarily attributable to the patents and technical know-how, trademarks and customer relationship we recognized in our acquisition of APT Medical Inc. in 2024.
Our goodwill remained at RMB11.6 million in 2023, 2024 and 2025.
Financial Information · p. 231
The headroom amounted to RMB17.4 million, RMB7.8 million and RMB14.0 million as of December 31, 2023, 2024 and 2025, respectively.
Financial Information · p. 232
If the revenue annual growth rate decreased from 6.61% to 3.25%, from 5.88% to 5.84% and from 10.23% to 10.19% or the average gross margin (including warranties) decreased from 15.83% to 15.51%, from 15.16% to 15.05% and from 14.21% to 13.69%, or the pre-tax discount rate increased from 11.76% to 12.44%, from 10.25% to 10.47% and from 10.36% to 10.73%, an impairment on goodwill would be recognized in 2023, 2024 and 2025, respectively.
We completed the first step of the acquisition in April 2024 at a cash consideration of RMB60.0 million, which resulted in a goodwill of RMB20.4 million that represented the difference of such cash consideration and the value of identifiable net assets of D-infuture Tech acquired at the acquisition date of RMB39.6 million.
Financial Information · p. 231
We engaged an independent qualified professional valuer to assist the preparation of the goodwill impairment testing.
Financial Information · p. 232
The headroom of the recoverable amounts over the carrying amount of the D-infuture Tech as at December 31, 2024 and 2025 are RMB77.3 million and RMB61.4 million, respectively.
As of December 31, 2023, 2024 and 2025, we had goodwill of RMB242.4 million, RMB364.3 million and RMB368.9 million.
Financial Information · p. 209
Management engaged independent external valuers to assess the recoverable amounts of goodwill as at the end of each year.
Financial Information · p. 211
The management has considered and assessed reasonably possible changes for key assumptions and has not identified any instances that could cause the carrying amount of each CGU to exceed its respective recoverable amount.
We recorded goodwill of RMB297.0 million as of December 31, 2024 and RMB297.0 million as of December 31, 2025. Our acquired goodwill arose from our acquisitions of Taihe Intelligent.
Financial Information · p. 268
The estimated recoverable amount of the CGU related to Taihe Intelligent exceeded its carrying amount by approximately RMB14,600,000 and RMB17,591,000 as at December 31, 2024 and 2025, respectively.
Financial Information · p. 269
If the reference market price had been 3.23% and 3.84% lower than management’s estimates as of December 31, 2024 and 2025, we would have had to recognize an impairment loss against the carrying amount of goodwill.
At December 31, 2023, 2024 and 2025, the Group performed impairment tests on the CGUs containing capitalized development cost by assessing the recoverable amounts of the assets comprising the CGU in relation to its intelligent city cluster multi-modal transit solutions products and service line, which included the capitalized development costs.
Financial Information · p. 228
The headroom calculated based on the recoverable amounts deducting the carrying amount of the Guangdong Huazhiyuan CGU as at December 31, 2023, 2024 and 2025 is RMB135,824,000, RMB21,924,000, and RMB12,558,000.
Financial Information · p. 230
The headroom calculated based on the recoverable amounts deducting the carrying amount of the Qingdao Hisense Microunion CGU as at December 31, 2025 is RMB8,086,000.
Goodwill is tested by management for impairment annually or more frequently if events or changes in circumstances indicate that the carrying value may be impaired.
Financial Information · p. 228
Our Directors have performed sensitivity test by decreasing 5% of expected revenue, decreasing 5% of terminal growth rate or increasing 5% of pre-tax discount rate, with all other assumptions held constant.
Financial Information · p. 229
The recoverable amount of the CGUs exceeding their carrying amount is as follows:
Goodwill of RMB118.8 million resulted from the acquisition of T-mab Bio Pharma in September 2017 to further expand our market share of ADC drugs and antibody drugs.
Financial Information · p. 272
Based on the result of impairment assessment, there was no impairment on the goodwill for the T-mab Bio Pharma as of December 31, 2024 and 2025.
Financial Information · p. 273
Considering there was still sufficient headroom based on the assessment, management believes that a reasonably possible change in the above key parameters would not cause the carrying amount of the cash-generating units to exceed its recoverable amount.
The calculations use pre-tax cash flow projections based on financial budgets approved by management covering a five-year period.
Financial Information · p. 197
The headroom measured by the excess of the recoverable amount over the carrying amount of MFS CGU were RMB568.6 million, RMB531.6 million and RMB549.5 million as of December 31, 2023, 2024 and 2025 respectively.
Financial Information · p. 197
The headroom measured by the excess of the recoverable amount over the carrying amount of VGT Thailand CGU were RMB114.0 million and RMB210.8 million as of December 31, 2024 and 2025 respectively.
On January 1, 2021, we acquired 94% equity interests in Artmem Technology at a total consideration of RMB50,292,000, that exceeded fair value of 94% identifiable assets and liabilities of Artmem Technology, among which RMB7,086,000 was recognized as goodwill.
Financial Information · p. 244
As of December 31, 2023, 2024 and 2025, the amounts of headroom calculated based on the recoverable amounts deducting the carrying amount of the CGU are RMB89,669,000, RMB73,614,000 and RMB2,358,937,000, respectively.
Financial Information · p. 244
We believe that any reasonably possible change in any of these assumptions would not cause the carrying amount of Artmem Technology to exceed the recoverable amount of it for the years ended December 31, 2023, 2024 and 2025.
Our goodwill increased by 21.5% from RMB208.5 million as of December 31, 2023 to RMB253.3 million as of December 31, 2024 as a result of our acquisitions of Hangzhou Guan Tian, Suzhou Vida and Beijing Zhi Yang in 2024.
Financial Information · p. 226
Goodwill acquired through business combinations is allocated to two cash-generating units (“CGUs”) for impairment testing, which are intelligent manufacturing software solutions CGU and operations management software solutions CGU.
Financial Information · p. 226
The values assigned to the key assumptions on market development and discount rates are consistent with external information sources.
Our goodwill amounted to RMB38.2 million, RMB38.2 million and RMB38.2 million as of December 31, 2023, 2024 and 2025, respectively. We recorded goodwill of RMB38.2 million arising from the acquisitions of Beijing Bay Line of RMB34.3 million and Shanghai Asiacan of RMB3.9 million completed prior to the Track Record Period. The goodwill remained stable during the Track Record Period as no impairment indicators were identified.
As of December 31, 2023, 2024 and 2025, our book value of goodwill was mainly attributable to acquisition of Tenya HK (which is in relation to the mine operated by Heihe Luoke Mining), Jilin Banmiaozi Mining and Qinghai Dachaidan Mining.
Financial Information · p. 235
The value in use calculated is higher than the carrying amount for each CGU, accordingly, no impairment of goodwill was recognized during the Track Record Period.
Financial Information · p. 235
Management has undertaken sensitivity analysis on the impairment test of goodwill.
Our Group performs annual impairment assessments of the cash-generating unit group ("CGU group") to which goodwill, trademarks, and brands with indefinite useful life have been allocated.
Financial Information · p. 218
Our goodwill remained stable at RMB11,831.4 million, RMB11,440.0 million, and RMB11,643.5 million as of December 31, 2023, 2024, and 2025, respectively.
Financial Information · p. 234
Management has identified that a reasonably possible change in key assumptions could cause the carrying amount to exceed the recoverable amount for CGUs with significant goodwill.